Clinical Trial: 21239

Trial Status: Open
Disease Type: Lung
Trial ID 21239
Sponsor ID 61186372NSC3002

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

3 Locations

Locations

Arlington Office

Fairfax Office

Gainesville Office

Learn More About This Trial

Other Relevant Trials
Trial ID 61186372NSC3004
Sponsor ID Paloma 3

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

1 Location
Trial ID 21318
Sponsor ID Roche Laboratories, Inc.

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Principal Investigator
Timothy A. McCarthy, MD
5 Locations